Soligenix is continuously looking to expand its clinical development programs, and is seeking additional partners to out-license all or portions of our programs. We are keen to advance our products through development and onto the market in as many indications as possible.
Interested in one of our technologies – please send us an email for further details.
We would consider the following types of partnering possibilities with regard to each of our programs:
SGX942 in Oral Mucositis / SGX943 in Infectious Disease
Dusquetide is a proprietary 5-amino acid peptide for systemic delivery that regulates the innate immune system to reduce inflammation, eliminate infection and enhance tissue healing. Dusquetide is the active ingredient in both SGX942 and SGX943. Soligenix is seeking partners for therapeutic applications of SGX942 in all territories of the world.
Oral Beclomethasone 17,21-dipropionate (BDP) is a highly potent, topically active corticosteroid with a local effect on inflamed tissue provides a potent topical anti-inflammatory effect with less systemic toxicity than a comparably effective systemic corticosteroid. Soligenix is seeking partners for therapeutic applications of oral BDP such as Pediatric Crohn’s disease and acute radiation enteritis in all territories of the world.
Biodefense – RiVax® and CiVax™
Soligenix is seeking development partners for its ricin toxin vaccine (RiVax®) and its SARS-CoV-2 coronavirus vaccine (CiVax™) in all territories of the world. These could take the form of joint venture/co-development alliances or sublicenses.
Interested in one of our technologies – please email email@example.com for further details.